Aignostics obtains ISO 27001 recertification, underscoring commitment to information security

Aignostics today announced its successful recertification under the updated ISO/IEC 27001:2022 standard. Having previously earned ISO/IEC 27001:2017 certification in August 2022, this recertification demonstrates Aignostics’ continued commitment to world-class information security practices.

The updated ISO/IEC 27001:2022 standard includes critical changes addressing supply chain security enhancements, new cloud security controls, and data loss prevention controls. These changes are particularly significant for AI companies like Aignostics that operate complex machine learning pipelines. This recertification validates Aignostics' robust security infrastructure across its broad pipeline of products and services, ensuring enterprise biopharma clients can trust their data is protected by the highest security standards.

“As we expand our product offerings to oncology researchers worldwide, maintaining the highest standards of information security remains critical to our mission,” said Viktor Matyas, CEO of Aignostics. “We recognize that robust security isn’t just a requirement - it’s a foundation that enables breakthrough discoveries in cancer research. We are extremely proud of our Information Security and Compliance team and the whole organization who came together to achieve this certification.”

About Aignostics

Aignostics is an artificial intelligence company that turns complex pathology data into transformative insights. By combining proprietary access to multimodal clinical data, industry-leading technologies, and rigorous science, Aignostics develops best-in-class products and services for the next generation of precision medicine. Through collaborations with its biopharma partners, Aignostics supports drug discovery, translational research, clinical trials, and CDx development. Our latest product, Atlas H&E-TME, is a self-service application for comprehensive tumor microenvironment profiling in H&E images at single-cell resolution, empowering researchers with unprecedented precision and scalability. Established in 2018, Aignostics is a spin-off from Charité Berlin, one of the world’s largest and most esteemed university hospitals. Aignostics is funded by leading investors and has operations in Berlin and New York.

More information at: www.aignostics.com
‍Follow us on LinkedIn: www.linkedin.com/company/aignostics